Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CTSE | P14091 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153410 | 1.00 | REN (0.48) | RENCTSDCTSECA2BACE1 | |
| SCHEMBL3153401 | 1.00 | REN (0.48) | RENCTSDCTSECA2BACE1 | |
| SCHEMBL1432429 | 0.93 | CYP3A4 (0.42) | RENCTSDCTSECA2BACE1 | |
| SCHEMBL1433327 | 0.87 | TP53 (0.42) | RENCTSDCTSE | |
| SCHEMBL1432101 | 0.85 | CA2 (0.46) | RENCTSDCTSECA2BACE1 | |
| SCHEMBL1432085 | 0.85 | MASP2 (0.44) | RENCTSDCTSE | |
| SCHEMBL3141449 | 0.83 | REN (0.43) | RENCTSDCTSECA2 | |
| SCHEMBL3141442 | 0.83 | REN (0.43) | RENCTSDCTSECA2 | |
| SCHEMBL3141428 | 0.83 | REN (0.43) | RENCTSDCTSECA2 | |
| SCHEMBL3141433 | 0.83 | REN (0.43) | RENCTSDCTSECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | REN 1899/4885CTSD 2332/4885CTSE 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.